AG
ACHL

Artal Group’s Achilles Therapeutics ACHL Stock Holding History

Artal Group’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-755,375
Closed -$616K – 107
2024
Q2 		$616K Hold
755,375
– – 0.02% 99
2024
Q1 		$944K Sell
755,375
-1,500,000
-67% -$1.62M 0.02% 95
2023
Q4 		$2M Hold
2,255,375
– – 0.07% 64
2023
Q3 		$2.05M Hold
2,255,375
– – 0.09% 67
2023
Q2 		$2.13M Hold
2,255,375
– – 0.07% 83
2023
Q1 		$2.16M Hold
2,255,375
– – 0.13% 79
2022
Q4 		$2.03M Hold
2,255,375
– – 0.11% 88
2022
Q3 		$5.1M Hold
2,255,375
– – 0.22% 60
2022
Q2 		$5.68M Hold
2,255,375
– – 0.3% 53
2022
Q1 		$6.63M Hold
2,255,375
– – 0.28% 69
2021
Q4 		$11.3M Hold
2,255,375
– – 0.31% 66
2021
Q3 		$17.6M Hold
2,255,375
– – 0.39% 60
2021
Q2 		$22.1M Hold
2,255,375
– – 0.45% 48
2021
Q1 		$37.3M Buy
+2,255,375
New +$37.3M 0.66% 36

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Artal Group's ACHL Position: Q3 2024 in Review

Artal Group sold out of Achilles Therapeutics (ACHL) in Q3 2024, closing a stake of 755,375 shares — an estimated $616K sold.

Artal Group first reported a position in ACHL in Q1 2021 and held it in 14 quarters. The position peaked at $37.3M in Q1 2021. 22 funds tracked by Wall St. Rank hold ACHL as of Q3 2024.

  • Artal Group reported no remaining Achilles Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 755,375 Achilles Therapeutics shares in Q3 2024, an estimated $616K.
  • Artal Group first reported a position in Achilles Therapeutics in Q1 2021 and held it in 14 quarters.
  • Artal Group's Achilles Therapeutics position peaked at $37.3M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.